# Ligufalimab and Cadonilimab in Advanced Liver Cancers

Source: https://onco.cc/trials/nct06789848/  
OnCo record `nct06789848` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cadonilimab in gallbladder cancer and other biliary tract cancers, run by University of Texas Southwestern Medical Center, now recruiting.

## Summary

Ligufalimab and Cadonilimab in Advanced Liver Cancers is a phase 2 interventional study registered as NCT06789848 by University of Texas Southwestern Medical Center, with a registry enrolment figure of 64 participants, started 2025-02-18 and due to reach its primary completion in 2029-05-31. Interventions recorded: Ligufalimab, Cadonilimab. Conditions listed: Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer. Gallbladder cancer is named in the registry entry: "* Cohort B (BTC, biliary tract cancers): Patients must have histologically confirmed biliary tract cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancers). Patients w". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06789848
- Phase: 2
- Setting: Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers
- Sponsor: University of Texas Southwestern Medical Center
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT06789848: https://clinicaltrials.gov/study/NCT06789848

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06789848.json